7,503 Shares in Tempus AI, Inc. (NASDAQ:TEM) Purchased by Circle Wealth Management LLC

Circle Wealth Management LLC bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 7,503 shares of the company's stock, valued at approximately $253,000.

Several other hedge funds have also recently added to or reduced their stakes in TEM. Franklin Resources Inc. boosted its stake in Tempus AI by 1.0% during the 3rd quarter. Franklin Resources Inc. now owns 811,311 shares of the company's stock valued at $45,920,000 after purchasing an additional 8,387 shares during the period. Green Alpha Advisors LLC acquired a new position in Tempus AI in the 4th quarter valued at approximately $1,090,000. FNY Investment Advisers LLC acquired a new position in Tempus AI in the 4th quarter valued at approximately $67,000. Bouvel Investment Partners LLC acquired a new position in Tempus AI in the 4th quarter valued at approximately $1,029,000. Finally, Avanza Fonder AB acquired a new position in Tempus AI in the 4th quarter valued at approximately $1,197,000. Institutional investors own 24.22% of the company's stock.

Tempus AI Trading Down 5.9%

TEM stock traded down $3.88 during midday trading on Friday, hitting $61.34. 15,472,133 shares of the company's stock were exchanged, compared to its average volume of 6,015,116. The stock's fifty day moving average price is $48.39 and its 200-day moving average price is $51.05. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market cap of $10.56 billion and a PE ratio of -7.86. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03. The business had revenue of $255.74 million for the quarter, compared to the consensus estimate of $248.13 million. The company's revenue was up 75.4% compared to the same quarter last year. Research analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Bank of America upped their price target on Tempus AI from $54.00 to $60.00 and gave the company a "neutral" rating in a report on Monday, March 3rd. BTIG Research assumed coverage on Tempus AI in a report on Monday, April 21st. They issued a "buy" rating and a $60.00 price target for the company. Morgan Stanley upped their price target on Tempus AI from $60.00 to $65.00 and gave the company an "overweight" rating in a report on Friday. Needham & Company LLC reissued a "buy" rating and issued a $70.00 target price on shares of Tempus AI in a report on Wednesday. Finally, TD Cowen reissued a "buy" rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $61.50.

Insiders Place Their Bets

In related news, CAO Ryan M. Bartolucci sold 6,059 shares of Tempus AI stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $80.00, for a total value of $484,720.00. Following the sale, the chief accounting officer now owns 47,000 shares of the company's stock, valued at approximately $3,760,000. The trade was a 11.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jennifer A. Doudna sold 1,320 shares of Tempus AI stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $90.00, for a total value of $118,800.00. Following the completion of the sale, the director now directly owns 36,011 shares in the company, valued at approximately $3,240,990. This represents a 3.54% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,237,561 shares of company stock worth $251,210,331. Corporate insiders own 27.60% of the company's stock.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.